This report on psychedelics as medicine, brought to you by Prohibition Partners, is an industry first, profiling all major psychedelic drugs, both naturally derived plant-based
varieties (entheogens) such as psilocybin, ibogaine, ayahuasca and mescaline, along
with those synthetically manufactured in laboratory settings, such as LSD (lysergic
acid diethylamide), ketamine and MDMA (Methylenedioxymethamphetamine). The psychedelics profiled here share many features in common, most notably their
hallucinogenic properties and their ability to alter levels of serotonin activity (a neurotransmitter) in the brain.

Once the darling of the medical community, psychedelics fell out of favour when they
were adopted by the ‘hippie’ counterculture of the 1960s. Their status as illicit substances was then codified in the Convention on Psychotropic Substances of 1971. In 2020, however, psychedelics are experiencing a radical renaissance. Our report identifies the changing legal and regulatory frameworks within which psychedelics are currently controlled. It provides expert analysis of the overwhelming evidence from advanced clinical trials, which supports the potential of each of the psychedelics profiled to disrupt conventional treatments for a wide array of debilitating mental health conditions, affecting hundreds of millions of people worldwide.

Finally, it offers key insights into the extraordinary opportunities that psychedelics will present to early movers in this nascent industry, including interviews with pioneering
experts already operating in the therapeutic psychedelics space.